Novartis | NOVN - Interest Expense On Debt


Novartis reported $468M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Alcon AG USD 53M 1000K Jun/2026
Amgen USD 653M 94.99B Sep/2026
AstraZeneca USD 371M 31M Sep/2026
Autolus Therapeutics Ltd USD 11.12M 11.71M Mar/2026
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 403M 4M Sep/2026
Eli Lilly USD 316M 201.3M Sep/2026
Fresenius EUR 81M 5M Sep/2025
Fresenius Medical Care EUR 97.5M 14.5M Sep/2026
Genmab DKK 139M 129M Jun/2026
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
J&J USD 43M 25M Mar/2026
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 137M 33M Jun/2026
Merck USD 525M 46M Jun/2026
Novartis USD 468M 6M Sep/2026
Novartis USD 281M 8M Sep/2025
Novo Nordisk DKK 1.5B 28M Jun/2026
Orion EUR 300K 400K Sep/2026
Pfizer USD 662M 5M Sep/2026
Philips EUR 84M 1000K Sep/2026
Recordati EUR 22.13M 1.43M Dec/2025
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 222M 65M Sep/2026
UCB EUR 49M 29M Dec/2025